BIOSOLVE-IV study confirms excellent safety, efficacy profile of Biotronik’s Magmaris Resorbable Magnesium Scaffold
Biotronik presented data from the full-cohort 2-year BIOSOLVE-IV study in a poster session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2022. Principal investigator Prof. Dr Johan Bennett presented the recent findings and highlighted the low TLF rate and the low scaffold thrombosis rate of Magmaris Resorbable Magnesium Scaffold (RMS).
